IFF is showing better operating momentum as Taste, Scent, and Health & Biosciences grow, but heavy debt and a still-premium valuation keep the stock at Hold.
International Flavors & Fragrances Inc. (IFF) is a Hold for moderate-risk investors with a medium-term horizon. The investment case rests on a sharper portfolio, improving operating momentum, and a credible path to lower leverage. The counterweight is valuation: trailing earnings remain weak, net debt is substantial, and the stock already reflects part of the expected recovery.
The operating trend improved in the first half of 2026. Continuing-operations sales rose 4%, EBITDA increased 8%, and second-quarter revenue reached approximately $2.0B with adjusted operating EBITDA of $408M and a 20.9% margin. Taste, Scent, and Health & Biosciences all delivered growth in the quarter. That breadth matters more than a single strong product cycle.
The main catalyst is the planned divestiture of Food Ingredients to CVC at an enterprise value of approximately $4.3B, or about 10x EBITDA. IFF plans to use more than $1B of proceeds to reduce debt and has authorized $2.5B of share repurchases. That capital allocation can improve per-share earnings, but the company will also carry approximately $100M of stranded costs until its remediation plan is completed.
That statement from CEO Jon Erik Fyrwald captures the opportunity and the risk. IFF has demonstrated volume and productivity progress, but investors still need sustained earnings conversion. The forward P/E of 23.0x is reasonable for a successful recovery, less so if revenue remains modest and deleveraging takes longer than planned.
IFF is a New York-based specialty chemicals company founded in 1909 and listed on the NYSE under IFF. It employs approximately 21,500 people and sells flavor, fragrance, health, bioscience, and related formulation products internationally.
The 2025 segment data shows the scale of the reshaping. Food Ingredients generated $3.3B of revenue, Health & Biosciences produced $2.3B, Scent generated $2.5B, and Taste generated $2.5B. The continuing company will therefore be smaller than the historical IFF, but its mix will be more concentrated in the businesses management describes as higher growth and higher margin.
Taste generated second-quarter sales of $688M, up 4%, with growth in every region and double-digit performance in Asia. EBITDA reached $124M, up 6%, helped by volume growth and favorable net pricing. New customer wins and higher sales to existing customers supplied the commercial engine.
Health & Biosciences produced sales of $601M, up 5%, and EBITDA of $150M, up 6%. Grain Processing, Food Biosciences, and Animal Nutrition were notable contributors. This segment gives IFF exposure to enzymes, cultures, probiotics, specialty ingredients, and animal nutrition, where technical performance and formulation support are central to customer decisions.
Scent reported sales of $665M, up 8%, and EBITDA of $134M, up 5%. Fragrance Ingredients grew more than 20%, while Consumer Fragrance posted high single-digit growth. Fine Fragrance grew at a low-single-digit rate despite the Middle East conflict. The Scent result was strong, although part of the Fragrance Ingredients gain benefited from a comparison against a prior-year decline of more than 10%.
The three continuing segments produced approximately $2.0B of second-quarter sales in aggregate. Management expects 2026 continuing-operations sales of $7.4B to $7.6B and EBITDA of $1.53B to approximately $1.6B. The guidance shows a business with solid momentum, but also a portfolio whose reported revenue will look lower after the divestitures.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
IFF does not rely on one consumer-facing branded product. Its flagship offering is the formulation platform that helps food, beverage, personal-care, household, and health customers create finished products. The strongest recent examples were Taste new wins, Fragrance Ingredients growth, and Health & Biosciences expansion in Food Biosciences and Animal Nutrition.
Taste illustrates the value of application-led selling. The segment grew 4% in the second quarter, with volume growth on existing business and strong new wins. Because flavors are incorporated into products such as soups, sauces, beverages, sweets, dairy products, and snacks, IFF participates in a wide range of customer launches rather than depending on one end product.
Scent offers the clearest near-term growth signal. Fragrance Ingredients grew more than 20% in the second quarter, although management credited both strategic use of the synthetics portfolio and a favorable comparison. The company expects that growth to normalize toward higher-value ingredients in the second half, making the quality of future growth more important than the headline quarterly increase.
Health & Biosciences provides a different form of product leverage. Its enzymes, cultures, probiotics, and specialty ingredients serve food, home and personal care, animal nutrition, and grain processing applications. Second-quarter growth across those businesses shows that IFF is not dependent solely on discretionary fragrance demand.
IFF's competitive advantage is built on formulation science, customer co-development, global application laboratories, regulatory expertise, and a broad portfolio of natural and biotechnology-based solutions. Company materials identify approximately 3,000 employees working in R&D, 849 granted U.S. patents, and 451 U.S. patent applications as of December 31, 2025.
This technical base matters because customers often need more than a raw ingredient. They need a solution that performs in a particular recipe, scent profile, manufacturing process, and regulatory environment. IFF's application support and global customer network can make a formulation change costly in time and testing, which supports customer retention.
The portfolio simplification should improve the return on that innovation platform. Management said a simplified customer base and manufacturing network will allow IFF to accelerate innovation, increase R&D focus, improve execution, and enhance free cash flow conversion. That is a logical benefit of the transaction, although the approximately $100M of stranded costs will temporarily dilute the result.
The quote reflects a credible strategy, but execution remains the test. Management plans to remove about two-thirds of the stranded costs within the first 12 months after closing and the remainder within the second full year.
IFF operates a global manufacturing and customer-support network across Taste, Scent, and Health & Biosciences. Its second-quarter performance was supported by volume growth and productivity gains, while cash generation benefited from better inventory management and tighter accounts receivable and accounts payable controls.
The separation of Food Ingredients creates short-term operational friction. Management identified the unwind of factoring agreements, possible inventory builds, and supplier prepayments before the early 2027 stand date. Those actions can reduce near-term cash conversion even though they are transaction-related rather than evidence of deterioration in the remaining businesses.
IFF also faces raw-material, transportation, energy, tariff, and geopolitical exposure. In the second quarter, higher Brent crude prices and supply-chain disruptions helped the synthetics portfolio capture sales in Fragrance Ingredients. That benefit also demonstrates the other side of the equation: input volatility can change product mix and margin quality quickly.
The operations plan includes redesigning processes, simplifying systems, reviewing third-party contracts, and aligning the remaining cost structure with the smaller portfolio. Those actions are concrete, but the $100M cost burden means the separation will remain an operating issue through the medium term.
IFF participates in specialty ingredients markets tied to food, beverage, fragrance, personal care, nutrition, and biosciences. McKinsey data cited in the supplied market research places flavors and fragrances, surfactants, and life-science additives at approximately 2% to 3% growth over the prior 18 months and approximately 3% to 6% growth in the first half of 2026.
Broader specialty chemicals market estimates also show a growing opportunity. Mordor Intelligence estimates a global specialty chemicals market of $1.26T in 2026 and $1.54T in 2031, while MarketsandMarkets uses a narrower definition and estimates $285.4B in 2023 and $364.8B in 2028. The different market sizes reflect scope, but both estimates place the category on a growth path.
The relevant demand drivers for IFF are cleaner-label products, natural ingredients, functional nutrition, biotechnology, premium fragrances, and formulation solutions that improve product performance. These are visible in IFF's operating portfolio and in the second-quarter growth reported by Taste, Scent, and Health & Biosciences.
The market is not uniformly defensive. IFF's 2025 revenue declined to $10.9B from $11.5B in 2024, while management cited a softer second-quarter outlook for Fine Fragrance because of the Middle East conflict and a difficult comparison. The company has exposure to consumer demand, but its diverse applications reduce reliance on any single product category.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
IFF serves manufacturers of dairy products, meat, beverages, snacks, bakery products, candy, personal-care products, household products, dietary supplements, animal nutrition products, and industrial biotechnology applications. Its offerings are typically inputs or formulations inside a customer's finished product.
The customer base is broad. IFF's 2025 annual filing states that no customer represented 10% or more of consolidated net sales. That reduces the risk that one account determines the entire income statement, although large multinational customers can still exert pricing and innovation pressure.
Customer relationships are supported by co-development and application work. Second-quarter Taste growth came from both new wins and higher volume on existing business, while Health & Biosciences grew across all businesses. Those figures support the view that IFF's customer model includes recurring programs as well as individual product launches.
Customer purchasing is still sensitive to consumer demand, inflation, input costs, and inventory decisions. CEO Jon Erik Fyrwald said consumer demand remained resilient in 2026 and that customers had not reported significant changes, while also acknowledging that inflationary and geopolitical risks could change that pattern.
IFF identifies Givaudan, dsm-firmenich, Symrise, Kerry, ADM, and Novonesis among its principal competitors. Regional flavor houses, fragrance specialists, ingredient suppliers, and customer-owned development teams add further competition.
Givaudan, dsm-firmenich, and Symrise are the closest global comparisons in flavors and fragrances. Kerry and ADM have stronger exposure to food systems and ingredient solutions, while Novonesis is particularly relevant to enzymes and biosolutions. IFF's advantage is breadth across Taste, Scent, and Health & Biosciences, but that breadth has historically created more operating complexity.
Competition centers on innovation, product quality, regulatory compliance, customer service, application support, and consumer insight. IFF's R&D workforce, patent portfolio, global footprint, and second-quarter volume growth support a strong competitive position. The company still must prove that the streamlined portfolio can produce margins closer to the strongest focused peers.
The Food Ingredients divestiture should make that comparison easier. Investors will see a company centered on three businesses rather than a larger collection of ingredient activities. Management also retained 10% ownership of the divested Food Ingredients business, preserving an economic link without retaining full operating responsibility.
The most direct geopolitical risk in the supplied data is the Middle East conflict. Fine Fragrance grew slightly in the second quarter despite that pressure, but management expects a softer third quarter and a recovery in the fourth quarter. This creates a specific near-term risk to Scent rather than a broad claim about all end markets.
Foreign exchange is a near-term support. IFF's 2026 guidance assumes approximately a 1% positive impact from currency on sales growth and approximately a 2% positive impact on EBITDA growth. That benefit is helpful, but it is not the same as underlying volume or pricing progress.
Input-cost volatility remains material. Management cited higher Brent crude prices and supply-chain disruptions in explaining the Fragrance Ingredients mix, while IFF's filings identify raw materials, energy, transportation, tariffs, and trade actions as operating risks. The company can pass through some costs, but the second-quarter segment results show that price-to-input cost can still affect profitability.
The macro backdrop therefore favors IFF's specialty, innovation-led businesses but does not remove cyclicality. The 2026 continuing-operations guidance of 2% to 4% sales growth and 4% to 8% EBITDA growth is a measured outlook rather than an aggressive expansion case.
Net debt remains substantial, but the planned Food Ingredients sale should help IFF use more than $1B of proceeds to reduce leverage while it carries about $100M of stranded costs.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Continuing-operations sales rose 4% and EBITDA increased 8% in the first half of 2026, with second-quarter adjusted operating EBITDA of $408M and a 20.9% margin.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is guiding to 2026 continuing-operations sales of $7.4B to $7.6B and EBITDA of roughly $1.53B to $1.6B, implying solid but not explosive growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →IFF trades at a forward P/E of 23.0x, which looks reasonable if the recovery holds but less compelling if deleveraging and earnings conversion take longer.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework points to $95 as fair value, with upside requiring stronger earnings conversion and a cleaner balance sheet after divestitures.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →IFF is becoming a cleaner investment story. The company is exiting Food Ingredients, focusing on Taste, Scent, and Health & Biosciences, and using transaction proceeds to reduce debt and repurchase shares. First-half 2026 volume growth, 8% EBITDA growth, and $378M of free cash flow provide evidence that the operating reset is gaining traction.
The balance sheet and income statement still prevent an outright Buy at the present valuation. Debt remains high relative to cash, 2025 produced a net loss, and the company must remove approximately $100M of stranded costs while managing separation-related working-capital pressure.
For moderate-risk investors, the disciplined stance is to Hold near $95 and demand a wider margin of safety before adding aggressively. A successful close of the Food Ingredients transaction, sustained growth in the three core segments, and visible debt reduction would strengthen the case for a higher valuation. Until those gains are reflected in recurring earnings, IFF remains a credible recovery story priced close to its current fair value estimate of $95.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
International Flavors & Fragrances Inc. (IFF) beat EPS and revenue estimates, but shares slipped as investors looked past the headline to softer fourth-quarter profit guidance and a revenue outlook still below the Street’s midpoint. Our deep dive breaks down segment growth, margin trends, and what the updated guidance really signals.
International Flavors & Fragrances Inc. (IFF) drops 5.9% after reporting earnings beats, as investors react to the latest quarterly results and outlook.
Keith Kohl’s Angel Publishing promotion for Technology and Opportunity, The AI Survivors, names three companies that supposedly can outlast the AI bubble. We test the claim against their filings.